As 2026 gets under way, it might be a good time to highlight some of our 2025 success stories.
These will be somewhat generic explanations as nearly all of these are covered with Non-Disclosure Agreements.
-
- Two of our 2025 economics projects resulted in research publication early this year. (See separate announcements for these.)
- We provided cost analytics that along with clinical explanations that enabled Medicare to make changes to certain payment policies. As the result, more patients potentially will have access to life-savings treatments.
- We worked with another company to help them better understand patient demographics and economics for a rare disease. This work helps paint a broader understanding of treatment options and disease progression. Not only did the research result in a poster for a major conference, the poster won an award for presentation.
- We helped another company verify and understand mortality and economic costs of certain types of surgeries. This economics understanding should go a long ways toward helping patient outcomes as well as controlling hospital costs.
- We helped a number of early stage start-up companies better understand the economics of their new devices or treatments. We were able to assist them in better understanding their pathway to patient care and marketplace acceptance.
- It was a busy year, and 2026 proves to be equally as fruitful.
Barth Syndrome affects males who often fail to thrive as children and face numerous healthcare challenges as they age. Few make it past age 40. Because it is so rare, there has been little previous research into the disease costs and treatments.